Why GLP-1s work well in PCOS
PCOS sits at the intersection of hyperinsulinemia, obesity, and hyperandrogenism. Insulin drives ovarian theca cells to produce testosterone; testosterone disrupts ovulation; disrupted ovulation disrupts progesterone; and the metabolic load compounds. Weight loss breaks the loop. GLP-1 and GIP/GLP-1 co-agonists lower insulin by reducing adiposity and by delaying gastric emptying, which blunts the post-meal insulin spike. That does two useful things at once for PCOS: lowers androgen load and restores cyclicity in many patients.
PCOS patients in GLP-1 trials (usually as part of broader obesity populations) typically respond as well as or slightly better than non-PCOS patients. The insulin-resistance phenotype is a known responsive subgroup.
Dosing and timing considerations specific to PCOS
Standard titration applies: semaglutide 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly; tirzepatide 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly. What’s specific to PCOS is the TTC timing: if you’re trying to conceive, discontinue semaglutide at least 2 months before attempting, and tirzepatide at least 1 month before attempting. Both drugs are classified as not recommended during pregnancy. The pregnancy-timeline calculator walks through a structured taper plan.
What to discuss with your clinician
- Baseline labs: A1C, fasting insulin, HOMA-IR, lipids, CMP, TSH, LH/FSH ratio, total and free testosterone, DHEA-S, SHBG.
- Whether to continue or layer metformin (most endocrinologists keep it) and inositol (often continued).
- Contraception plan if you’re not actively TTC — restoring ovulation can surprise you.
- Follow-up cadence: q4 weeks during titration, q3 months at maintenance.
- Muscle preservation plan: 1.2–1.6 g/kg protein and 2–3 resistance sessions per week.
The cost paths in 2026
If your BMI qualifies for AOM coverage (≥ 30, or ≥ 27 with comorbidity), push for Wegovy or Zepbound through insurance with a proper PA packet. If not, manufacturer vials are the cheapest reliable cash path: LillyDirect sells Zepbound vials at $349 (2.5 mg) or $499 (5–15 mg); NovoCare sells Wegovy 1.7 mg / 2.4 mg vials at $499. Compounded peptides exist at $199–$449 via telehealth but face continuity risk after the 2024–2025 FDA shortage delisting. HSA/FSA dollars stretch any of these paths by ~22–32%.